http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
-
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
-
Exelixis (EXEL) Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at
-
Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO
-
Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021
-
UPDATE: FDA Approves Exelixis's (EXEL) CABOMETYX for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
-
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
-
Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on Chec
-
Exelixis Statement on the Passing of Two Senior Executives
-
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
-
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell C
-
Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology
-
Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
-
Exelixis (EXEL) Announces FDA Accepts for Priority Review sNDA for CABOMETYX for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
-
Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differen
-
Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
-
Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021
-
Exelixis (EXEL) and Ipsen Report Mixed Results with Cabozantinib in Combination with Immune Checkpoint Inhibitor in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Live
-
Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previo
-
Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previo
-
Exelixis (EXEL) Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence
-
Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence
-
Exelixis (EXEL) Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb (BMY) to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
-
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
-
Exelixis (EXEL), Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer P
-
Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Prese
-
Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Prese
-
Exelixis (EXEL) Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX in Combination with OPDIVO as First-line Treatment for Patients with Advanced RCC
-
Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Pr
-
Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021
-
Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Pa
-
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
-
Exelixis (EXEL) Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
-
Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
-
Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update
-
Exelixis (EXEL) Announces Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target
-
Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target
-
Bristol Myers Squibb Reports First Quarter Financial Results for 2021
-
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
-
Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021
-
Exelixis (EXEL) Announces U.S. FDA Accepts IND Application for XB002 in Patients with Advanced Solid Tumors
-
Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors
-
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Ca
-
Exelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanc
-
Exelixis (EXEL) Announces Pact with Merck KGaA and Pfizer (PFE) to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Urothelial Carcinoma
-
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Ur
-
Exelixis (EXEL) Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline
-
Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline
-
Exelixis' (EXEL) Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX in Combination with OPDIVO as First-Line Treatment for Patients with Advanced RCC
-
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcino
